These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 34872567)

  • 1. Tumor antigens and immune subtypes guided mRNA vaccine development for kidney renal clear cell carcinoma.
    Xu H; Zheng X; Zhang S; Yi X; Zhang T; Wei Q; Li H; Ai J
    Mol Cancer; 2021 Dec; 20(1):159. PubMed ID: 34872567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of tumor-antigen signatures and immune subtypes for messenger RNA vaccine selection in advanced clear cell renal cell carcinoma.
    Xu Z; Wu Y; Chen X; Jin B
    Surgery; 2024 Sep; 176(3):785-797. PubMed ID: 38851900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development.
    Huang X; Tang T; Zhang G; Liang T
    Mol Cancer; 2021 Mar; 20(1):50. PubMed ID: 33685460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development.
    Ma S; Ba Y; Ji H; Wang F; Du J; Hu S
    Front Immunol; 2021; 12():738435. PubMed ID: 34603319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.
    Lin H; Wang K; Xiong Y; Zhou L; Yang Y; Chen S; Xu P; Zhou Y; Mao R; Lv G; Wang P; Zhou D
    Front Immunol; 2022; 13():773264. PubMed ID: 35185876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine.
    Zheng X; Xu H; Yi X; Zhang T; Wei Q; Li H; Ai J
    Mol Cancer; 2021 Dec; 20(1):160. PubMed ID: 34872584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LRP2 and DOCK8 Are Potential Antigens for mRNA Vaccine Development in Immunologically 'Cold' KIRC Tumours.
    Zhang S; Xia K; Chang Y; Wei Y; Xiong Y; Tang F; Peng J; Ouyang Y
    Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine.
    Zhong H; Liu S; Cao F; Zhao Y; Zhou J; Tang F; Peng Z; Li Y; Xu S; Wang C; Yang G; Li ZQ
    Front Immunol; 2021; 12():709986. PubMed ID: 34512630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development.
    Huang X; Zhang G; Tang T; Liang T
    Mol Cancer; 2021 Mar; 20(1):44. PubMed ID: 33648511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissection of tumor antigens and immune landscape in clear cell renal cell carcinoma: Preconditions for development and precision medicine of mRNA vaccine.
    Hu J; Mo Z
    Math Biosci Eng; 2023 Jan; 20(2):2157-2182. PubMed ID: 36899527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma.
    Zhou Q; Yan X; Zhu H; Xin Z; Zhao J; Shen W; Yin W; Guo Y; Xu H; Zhao M; Liu W; Jiang X; Ren C
    Theranostics; 2021; 11(20):9775-9790. PubMed ID: 34815785
    [No Abstract]   [Full Text] [Related]  

  • 12. Gene set enrichment analysis identifies immune subtypes of kidney renal clear cell carcinoma with significantly different molecular and clinical properties.
    Chen Z; Cao W; Luo J; Abdelrahman Z; Lu Q; Wang H; Wang X
    Front Immunol; 2023; 14():1191365. PubMed ID: 37426638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of tumor antigens and immune landscapes for bladder urothelial carcinoma mRNA vaccine.
    Sun Z; Jing C; Zhan H; Guo X; Suo N; Kong F; Tao W; Xiao C; Hu D; Wang H; Jiang S
    Front Immunol; 2023; 14():1097472. PubMed ID: 36761744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening.
    Han G; Zhao W; Song X; Kwok-Shing Ng P; Karam JA; Jonasch E; Mills GB; Zhao Z; Ding Z; Jia P
    BMC Genomics; 2017 Oct; 18(Suppl 6):678. PubMed ID: 28984208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive characterization of immune- and inflammation-associated biomarkers based on multi-omics integration in kidney renal clear cell carcinoma.
    Zhao E; Li L; Zhang W; Wang W; Chan Y; You B; Li X
    J Transl Med; 2019 May; 17(1):177. PubMed ID: 31133033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of tumor antigens and immune subtypes of acute myeloid leukemia for mRNA vaccine development.
    Wang F
    Clin Transl Oncol; 2023 Jul; 25(7):2204-2223. PubMed ID: 36781600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening of Tumor Antigens and Construction of Immune Subtypes for mRNA Vaccine Development in Head and Neck Squamous Cell Carcinoma.
    Li HX; Liu TR; Tu ZX; Xie CB; Wen WP; Sun W
    Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671475
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Klümper N; Ralser DJ; Bawden EG; Landsberg J; Zarbl R; Kristiansen G; Toma M; Ritter M; Hölzel M; Ellinger J; Dietrich D
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-omics analysis of tumor angiogenesis characteristics and potential epigenetic regulation mechanisms in renal clear cell carcinoma.
    Zheng W; Zhang S; Guo H; Chen X; Huang Z; Jiang S; Li M
    Cell Commun Signal; 2021 Mar; 19(1):39. PubMed ID: 33761933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cuproptosis status affects treatment options about immunotherapy and targeted therapy for patients with kidney renal clear cell carcinoma.
    Zhang G; Chen X; Fang J; Tai P; Chen A; Cao K
    Front Immunol; 2022; 13():954440. PubMed ID: 36059510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.